Fulcrum-Slate Merger Details: 5% Ownership, $270M Special Dividend, Pipeline Revealed
FULC sits 34% above its 52-week low of $2.83 on light trading volume (0.4× avg).
Summary
Fulcrum Therapeutics disclosed detailed merger terms with Slate Medicines: Fulcrum stockholders get ~5% ownership plus a ~$270M special dividend, while Slate brings a migraine-focused pipeline led by SLTE-1009 with Phase 1 data expected mid-2027.
Key Events · M&A and Partnerships · FULC
-
Merger Ownership Split
Pre-merger Fulcrum stockholders will own ~5% of the combined company, pre-merger Slate stockholders ~55.9%, and concurrent private placement investors ~39.1%.
-
Special Cash Dividend
Fulcrum intends to pay a special cash dividend of approximately $270M to pre-merger Fulcrum stockholders from additional cash at close, while contributing $20.3M net cash for its 5% stake.
-
Slate Pipeline Revealed
Slate's lead program SLTE-1009 is a PACAP/VIP dual-targeting monoclonal antibody for migraine prevention, with Phase 1 data expected mid-2027 and Phase 2 in H2 2027. SLTE-2100, a PACAP/VIP and CGRP bispecific, enters clinical trials in H2 2027.
-
Combined Company Details
The combined company will be renamed Slate Medicines, Inc., trade on Nasdaq under ticker SLTE, and is expected to have cash runway into 2029.
Analysis · FULC · Life Sciences
This 425 filing provides the first detailed terms of the Fulcrum-Slate merger announced earlier today. Fulcrum stockholders will own only ~5% of the combined company, receiving a special cash dividend of approximately $270M from the concurrent $245M private placement. Slate's lead program SLTE-1009 targets PACAP/VIP for migraine prevention, with Phase 1 data expected mid-2027. The combined company is expected to trade as SLTE on Nasdaq with cash runway into 2029. This is a transformative event for Fulcrum, which became a shell company after discontinuing its lead program in June 2026.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 41.9% of the 322 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FULC was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $285.4M. The 52-week trading range was $2.83 to $15.74. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.